Zoetis, Inc. (ZTS) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: The bar is low heading into Q2 — consensus has been revised down sharply since the Q1 miss — but the setup remains binary: any sign that U.S. companion animal demand is stabilizing (vet visits, Librela sequential growth, derm share) could spark a relief rally, while a second consecutive miss would likely re-test the post-Q1 lows.

Zoetis enters Q2 2026 earnings with sentiment near multi-year lows following the sharp Q1 miss and guidance cut in May. Management explicitly guided for Q2 organic growth to be "highly reflective of Q1" — essentially flat to slightly negative — making the bar for a beat relatively low on the headline. The key debate is not whether Q2 is weak (it will be), but whether the trajectory of the U.S. companion animal business is improving enough to validate the back-half recovery thesis. Consensus sits at $2.50B in revenue and $1.86 in adjusted diluted EPS, both modestly below the post-Q1 guidance midpoint, suggesting the Street has already priced in a difficult quarter. The stock has declined ~15% since the Q1 print and now trades at roughly 10.6x NTM P/E — the lowest multiple since the company's IPO — implying that a significant amount of bad news is already in the price. The single biggest wildcard is the trajectory of U.S. vet clinic visits: IDEXX's Q2 print (reported August 4) confirmed visit declines of ~1.5% in H2, consistent with Q2 trends, which is a modest negative read-through but not a deterioration. Elanco's Q2 results (reported August 5) showed the U.S. pet health market growing mid-single digits via omnichannel, suggesting the demand picture may be more nuanced than pure clinic-visit data implies. The cost and productivity program launched post-Q1 should provide some EPS cushion even if revenue disappoints.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus is a low bar on revenue ($2.50B, ~+1.6% YoY) and EPS ($1.86), with the Street already embedding near-zero organic growth for Q2. The bigger swing factor is U.S. companion animal — specifically whether Key Dermatology and Librela show any sequential improvement — rather than the headline numbers.

Table 1 — Current Quarter Snapshot (Q2 2026)

Source: Visible Alpha consensus and actuals data. SD = single digit. Q2 2026 consensus as of August 5, 2026.

Table 2 — Beat/Miss History: Top 2 KPIs (Last 8 Quarters)

Total Revenue

Adjusted Diluted EPS

Source: Visible Alpha consensus and actuals data. Pattern: ZTS had a strong 6-quarter beat streak before two consecutive misses in Q4 2025 and Q1 2026, both driven by U.S. companion animal weakness. The bar has been reset materially lower, and management has explicitly guided Q2 to look similar to Q1 on a growth-rate basis.

3. Guidance & Commentary Evolution

Key Takeaway: Guidance was cut materially at Q1 earnings (May 7) — revenue lowered by ~$200M at midpoint, EPS by ~$0.10 — and management has since confirmed at Stifel (May 28) and William Blair (June 2) that Q2 will look similar to Q1 with the recovery back-weighted to H2. No further formal guidance changes since Q1 earnings.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates have been revised sharply lower since the Q1 print — Q2 revenue consensus fell ~$40M and EPS fell ~$0.09 in the five trading days post-Q1 earnings — and have continued to drift lower through July. FY2026 consensus now sits near the low end of the revised guidance range, suggesting the Street is not giving management the benefit of the doubt on the H2 recovery.

Source: Visible Alpha consensus and actuals data. Estimates have been remarkably stable since the initial post-Q1 reset, suggesting the Street has fully digested the guidance cut and is not expecting further deterioration. The risk is that consensus is still too high on FY2026 if the H2 recovery does not materialize as management expects.

5. Stock Performance

Key Takeaway: The ~15% decline since the Q1 print (May 7) is almost entirely multiple compression — NTM P/E has fallen from ~18x to ~10.6x — as earnings estimates have been relatively stable post-reset. ZTS has dramatically underperformed both XLV (Healthcare ETF, +13.5% over the same period) and the S&P 500 (+5.2%), reflecting sector-specific headwinds rather than broad market weakness.

ZTS vs. XLV (Healthcare ETF) vs. S&P 500 — Indexed to 100 at Q1 2026 Earnings (May 7, 2026). Source: Yahoo Finance.

The chart above indexes all three series to 100 at the Q1 2026 earnings date (May 7, 2026). ZTS declined sharply in the days following the Q1 miss and guidance cut, then traded sideways in a narrow range of $71–$82 through July before drifting back toward the low $70s in early August. XLV rallied strongly over the same period (+13.5%), driven by broader healthcare sector rotation, while the S&P 500 gained +5.2%. The divergence highlights that ZTS's underperformance is company-specific rather than sector-driven. At ~10.6x NTM P/E (vs. a 10-year average of ~32x), the stock is pricing in a prolonged period of below-trend growth with no recovery premium.

6. Material News & Developments

Key Takeaway: The most important post-Q1 development is management's explicit confirmation at two investor conferences (Stifel, May 28; William Blair, June 2) that Q2 will look like Q1 on a growth-rate basis, removing any hope of a positive Q2 surprise from the macro side. The Neogen genomics acquisition and Lenivia/Portela early-experience launches are positive long-term signals but immaterial to Q2 numbers.

• May 7, 2026 — Q1 2026 Earnings Miss & Guidance Cut: ZTS reported Q1 revenue of $2.26B (vs. $2.31B consensus) and adj. EPS of $1.53 (vs. $1.61 consensus). Full-year revenue guidance cut to $9.68B–$9.96B from $9.83B–$10.03B; adj. EPS guidance cut to $6.85–$7.00 from $7.00–$7.10. Stock fell ~15% on the day. Management launched a comprehensive cost and productivity program. Implication: Sets a low bar for Q2 but raises the stakes for the H2 recovery narrative.
• May 7, 2026 — Neogen Animal Genomics Acquisition Announced: ZTS announced an agreement to acquire Neogen's animal genomics business, expanding its Precision Animal Health portfolio with a global genomics lab network. Expected to close in H2 2026; contribution described as "very marginal" to 2026 results. Implication: Strategically positive for livestock diagnostics long-term; immaterial to near-term numbers.
• Late May 2026 — Lenivia & Portela Early Experience Programs Launched: Early experience programs for the long-acting OA pain products (Lenivia for dogs, Portela for cats) commenced in select EU markets and Canada. Management applying a specialist-first approach, drawing lessons from the Librela launch. Full launch expected H2 2026; U.S. approval remains a 2027 expectation. Implication: Positive for the OA pain franchise long-term; early feedback described as "encouraging" but no revenue contribution in Q2.
• May 28, 2026 — Stifel Jaws & Paws Conference: CFO Wetteny Joseph confirmed Q2 organic growth rate expected to be "highly reflective of Q1" (essentially flat to slightly negative). Confirmed macro and competitive conditions expected to persist. Reiterated no broad price resets; loyalty programs being pivoted to point-of-sale discounts. Implication: Removes upside surprise risk for Q2 headline; confirms H2 recovery is comp-driven, not demand-driven.
• June 2, 2026 — William Blair Growth Stock Conference: CFO provided additional color: U.S. clinic visits down ~2% in Q1; clinic revenue up ~3% while visit volumes down ~3% (price masking volume). Simparica Trio share described as "very stable" with sequential improvement since H2 2025. Livestock expected mid-to-high single-digit growth for FY2026. Confirmed $1.8B remaining under share repurchase authorization. Implication: Nuanced picture — parasiticide headwinds are more macro than competitive; livestock remains a bright spot.
• June 10, 2026 — Chewy Q1 FY2026 Earnings: Chewy cut its FY2026 net sales outlook, citing a "more challenged" consumer pet environment with pressure on premiumization and product attach rates. Announced acquisition of Modern Animal (29 clinics), bringing total clinic count to 47 with plans to reach ~60 by year-end. Implication: Negative read-through on consumer pet spending; positive long-term read-through on clinic expansion.
• August 4, 2026 — IDEXX Q2 2026 Earnings: IDEXX raised FY2026 guidance (organic revenue growth 8.5–9.7%); guided for H2 U.S. clinic visit declines of ~1.5%, consistent with Q2 trends. Wellness visits down ~3% YoY; non-wellness visits showing modest growth. Aging pet population cited as a durable tailwind. Implication: Confirms vet visit headwinds persist but are not worsening; aging pet population supports chronic care demand (positive for Librela, OA pain).
• August 5, 2026 — Elanco Q2 2026 Earnings: Elanco raised FY2026 guidance to 6–7% organic constant currency growth; U.S. pet health expected to achieve "at least high single digit" growth for FY2026. Zenrelia (JAK inhibitor) gaining share in derm; Bafana (new derm product) demand running "double the size of expectations" but supply-constrained. Quattro (parasiticide) now in over half of U.S. clinics. Implication: Mixed — Elanco's strong derm performance confirms market demand exists but also confirms competitive pressure on ZTS's Apoquel/Cytopoint franchise.
• August 5, 2026 — Trupanion Q2 2026 Earnings: Trupanion confirmed "downturn in new visits to veterinarians reported across the industry" but raised FY2026 guidance; expanding deductible/co-insurance options to improve affordability. Pet insurance penetration growing. Implication: Confirms industry-wide visit headwinds; pet insurance expansion is a long-term positive for veterinary care utilization.

7. Peer Commentaries & Read-Throughs (Last 60 Days)

Key Takeaway: Peer commentary from Q2 2026 earnings (IDEXX, Elanco, Trupanion, Chewy) paints a nuanced picture: vet visit declines are real but stable (~1.5–3%), consumer pet spending is resilient in non-discretionary categories, and the derm market is growing — but Elanco's competitive products are gaining share. The read-through is modestly negative on volume, modestly positive on pricing discipline and market durability.

Note: Only commentary about the current or forward reporting quarter (Q2 2026 and beyond) is included below. Prior-quarter result discussions from peer earnings calls are excluded.

IDEXX Laboratories (IDXX) — Q2 2026 Earnings (August 4, 2026)

Relevance to ZTS: IDEXX is the leading veterinary diagnostics company and the best real-time indicator of U.S. vet clinic activity. Its forward guidance and commentary on visit trends, pet owner behavior, and the aging pet population are direct read-throughs to ZTS's companion animal business.

• U.S. Clinic Visit Outlook (H2 2026): IDEXX guided for H2 U.S. clinical visit declines of approximately 1.5%, "reflecting similar Q2 trends." Wellness visits remain the primary constraint (down ~3% YoY), while non-wellness visits are showing modest growth. ZTS Read-Through: Visit declines are not worsening from Q1/Q2 levels, which is consistent with ZTS management's expectation that macro conditions persist but do not deteriorate further. The wellness visit weakness is a headwind for preventive care products (parasiticides, derm), while non-wellness growth supports chronic care (Librela, OA pain).
• Aging Pet Population Tailwind: IDEXX highlighted that pets aged 5+ are contributing positive growth across both wellness and non-wellness visits, a trend consistent "for multiple quarters in a row." Management noted this "supports durable, increasing demand for diagnostics across dogs and cats." ZTS Read-Through: Positive for Librela and Solensia — older pets are the primary OA pain patient population. Also supports the long-term renal and oncology pipeline thesis.
• Consumer Behavior: IDEXX noted that "economic pressure that consumers are facing... put pressure on those discretionary categories" and that consumers are "slower to add or replace pets" during times of economic pressure. However, "the foundation of the overall pet population continues to be positive" and "pet owners remain committed to high quality care." ZTS Read-Through: Consistent with ZTS's own characterization of the macro environment. Slower pet population growth is a mild headwind for new patient starts in derm and parasiticides.
• Diagnostics Utilization as a Volume Lever: IDEXX emphasized that "only around one out of ten wellness visits are getting blood work today" and sees "inclusion as a long duration volume lever that does not depend on visit recovery." ZTS Read-Through: Positive for ZTS's diagnostics segment, which management has noted is growing faster than the overall company. The new next-gen chemistry instrument (expected H2 2026 launch) is well-timed to capture this opportunity.

Elanco Animal Health (ELAN) — Q2 2026 Earnings (August 5, 2026)

Relevance to ZTS: Elanco is ZTS's most direct animal health competitor, with competing products in dermatology (Zenrelia/JAK inhibitor, Bafana), parasiticides (Quattro), and OA pain. Elanco's forward commentary on market growth, pricing, and product uptake is the most direct competitive read-through available.

• U.S. Pet Health Market Growing Despite Visit Declines: Elanco stated the "growing U.S. pet health industry up mid-single digits for the trailing four quarters through Q1, with resilient pet owner spend and rational pricing." Management argued that "demand for pet health has always been broader than a singular metric like vet visits" and that "vet home delivery sales are growing nearly twice as fast as in-clinic sales." ZTS Read-Through: Constructive for the overall market, but ZTS is more clinic-dependent than Elanco given its product mix. The omnichannel shift benefits Elanco's retail-oriented products more than ZTS's clinic-administered biologics (Librela, Cytopoint).
• Pet Owner Spending Resilience: Elanco cited a recent survey showing "95% of surveyed owners said they would not cut spending on pet health, and 90% expect to maintain or increase spending over the next year." Elanco also noted a competitor "mid-season price increase" as evidence that the market believes pet owners are resilient. ZTS Read-Through: Positive for the long-term demand thesis, but ZTS's own Q1 data showed price sensitivity is real and broad-based. The survey data may reflect stated intent rather than actual behavior.
• Dermatology — Competitive Pressure on ZTS: Elanco's Bafana (new derm product) is seeing demand "double the size of expectations" with supply-constrained ramp. Zenrelia (JAK inhibitor) holds "JAK market share as high as 40%+ in Europe." Quattro (parasiticide) is now in "over half of U.S. clinics, up ten points since Q1." Elanco expects U.S. pet health to achieve "at least high single digit revenue growth" for FY2026. ZTS Read-Through: Directly negative for ZTS's Apoquel and Cytopoint franchises. Bafana's supply ramp and Zenrelia's share gains confirm that competitive promotional intensity in derm is not abating. Quattro's rapid clinic penetration is a headwind for Simparica Trio.
• Pricing Discipline: Elanco implemented its "largest price increase in the U.S. market in five years" at the start of 2026 and expects price to "accelerate in Q2 and continue in the back half." Described the marketplace as "remained responsible on pricing." ZTS Read-Through: Positive for the industry pricing environment. If competitors are raising prices, the gross-to-net compression ZTS experienced in Q1 may moderate, supporting ZTS's own price contribution in H2.

Trupanion (TRUP) — Q2 2026 Earnings (August 5, 2026)

Relevance to ZTS: Trupanion is the leading pet insurance provider in North America. Its commentary on vet visit trends, veterinary inflation, and pet owner spending behavior provides an independent data point on the companion animal market.

• Industry-Wide Visit Decline Confirmed: Trupanion CEO Margie Tooth explicitly noted "a downturn in new visits to veterinarians reported across the industry" but emphasized that "millions of uninsured puppies and kittens entering hospitals each year" represent a substantial addressable market. ZTS Read-Through: Confirms the visit headwind is real and industry-wide, not ZTS-specific. The focus on uninsured pets as an opportunity is consistent with ZTS's own view that the large untreated population represents long-term upside.
• Veterinary Inflation Still Elevated: Trupanion noted veterinary inflation is "still at the double digit level" (though normalizing), with clinics pushing prices to "maintain revenue strength" as wellness visits decline. ZTS Read-Through: Elevated clinic pricing is a double-edged sword for ZTS: it supports the price contribution to ZTS's revenue but also contributes to the pet owner price sensitivity that is suppressing visit volumes.
• Pet Insurance Expansion as a Long-Term Positive: Trupanion is expanding deductible and co-insurance options to improve affordability, with plans to roll out across North America by year-end. Expects to launch a new digital offering in H1 2027. ZTS Read-Through: Long-term positive — higher pet insurance penetration reduces the financial barrier to veterinary care, supporting demand for ZTS's premium pharmaceutical products. Not a Q2 catalyst.

Chewy (CHWY) — Q1 FY2026 Earnings (June 10, 2026)

Relevance to ZTS: Chewy is the largest online pet retailer and an increasingly important veterinary clinic operator. Its commentary on consumer pet spending, premiumization trends, and clinic expansion provides a retail-channel read-through to ZTS's companion animal business.

• Consumer Pet Environment "Incrementally More Challenged": Chewy cut its FY2026 net sales outlook, citing "a more appropriately conservative view of the consumer environment." Specifically noted "modest level of incremental pressure on premiumization and product attach rates" and expects this to "persist near term" into Q2 2026. Q2 2026 outlook assumes "current operating environment and consumer behavior trends remain generally stable." ZTS Read-Through: Negative for ZTS's premium companion animal products. Pressure on premiumization is consistent with ZTS's Q1 experience of pet owners shifting toward lower-cost alternatives in derm and parasiticides.
• Non-Discretionary Pet Health Remains Resilient: Chewy noted that "consumables and health care categories that are recurring in nature... continue to be super strong" and that "pet remains a resilient category, driven by recurring nondiscretionary needs." ZTS Read-Through: Positive for ZTS's chronic care products (Librela, Solensia, Apoquel for ongoing treatment) but less helpful for new patient starts in preventive care.
• Clinic Expansion Accelerating: Chewy closed the Modern Animal acquisition (29 clinics), bringing total to 47 clinics with plans to reach ~60 by year-end FY2026. CVC customers have year-1 NSPACs of ~$900, well above the company average. ZTS Read-Through: Long-term positive — more clinic touchpoints increase the opportunity for ZTS product prescriptions. Chewy's technology-enabled workflows may also increase diagnostic and treatment protocol utilization.

Peer Read-Through Summary

8. Insider Transaction Activity

Key Takeaway: Three directors made open-market purchases totaling ~$700K in the days immediately following the Q1 earnings miss — a notable signal of insider conviction at the post-miss lows. No insider sales have been reported since the Q1 print. The cluster of director buys near the $75–$80 range is a modest positive sentiment indicator.

Source: SEC Form 4 filings. All three transactions are discretionary open-market purchases (Form 4 code P), not 10b5-1 planned sales or compensation-related grants. The cluster of three director buys within a 3-day window immediately following the Q1 miss is notable — it suggests board-level conviction that the stock overreacted to the downside. No executive (CEO, CFO) purchases were reported, and no insider sales have been filed since the Q1 print.

9. Key Risks & Questions for the Call

Key Takeaway: The call will be binary around the H2 recovery narrative. Bulls need to hear that U.S. companion animal trends are improving sequentially; bears will focus on whether the guidance range is still achievable given the weak H1 and persistent competitive headwinds.

Key Risks

• H2 Recovery Fails to Materialize: Management's FY2026 guidance is heavily back-weighted to H2, driven by easier comps rather than a material improvement in underlying demand. If vet visit trends do not improve and competitive promotional intensity in derm and parasiticides persists, the guidance range may need to be cut again. This is the single largest risk to the stock.
• Dermatology Share Loss Accelerates: Elanco's Bafana is ramping supply rapidly and Zenrelia continues to gain share. If Apoquel loses more than the ~7% share already acknowledged, or if Cytopoint begins to see meaningful JAK-inhibitor switching, the derm franchise could face a more structural decline than management currently projects.
• Librela Recovery Stalls: U.S. Librela showed sequential growth for the first time in six quarters in Q1, but the absolute level ($37M in the U.S.) remains well below peak. If the sequential improvement does not continue in Q2, the OA pain franchise recovery thesis is at risk.
• FY2026 Guidance Range Too Wide to Be Useful: The current guidance range ($9.68B–$9.96B revenue; $6.85–$7.00 EPS) is unusually wide, reflecting management's acknowledged uncertainty. If Q2 comes in at the low end of the implied range, the market may price in a guidance cut even before one is announced.
• FX Headwinds: ZTS generates ~50% of revenue internationally. A stronger USD could create a meaningful headwind to reported results even if operational performance is in line.
• Cost Program Execution Risk: The comprehensive cost and productivity program is designed to deliver P&L leverage despite the top-line miss. If cost savings are slower to materialize than expected, EPS could disappoint even if revenue is in line.

Key Questions for Management

1. U.S. Companion Animal Trajectory: Can you provide any sequential data on U.S. vet clinic visits and therapeutic visit trends in Q2 vs. Q1? Are you seeing any improvement in the underlying demand environment, or is the H2 recovery purely a comp story?
2. Dermatology Share: Elanco's Bafana is ramping supply and Zenrelia is gaining share. Has the ~7% U.S. derm share loss stabilized, or are you seeing further erosion in Q2? What is the current trajectory of Apoquel vs. Cytopoint?
3. Librela Sequential Progress: Q1 showed the first sequential U.S. Librela revenue increase in six quarters. Did that sequential improvement continue in Q2? What is the current patient share trend?
4. Guidance Confidence: Given that H1 organic growth is tracking near zero, what gives you confidence that H2 can deliver the 4–6%+ organic growth implied by the full-year guidance range? Is the guidance range still the right range?
5. Lenivia/Portela Early Experience: What are the early readouts from the Lenivia and Portela launches in Europe and Canada? Are you seeing the specialist-first approach working as intended?
6. Cost Program Progress: Can you quantify the cost savings realized in Q2 from the comprehensive cost and productivity program? What is the expected run-rate savings for H2?
7. Capital Allocation: With $1.8B remaining under the share repurchase authorization and the stock at multi-year lows, what is the pace of buyback activity in Q2? Has the Neogen acquisition closed?

Disclosures & Data Sources

This document is prepared for informational purposes only and does not constitute investment advice. All financial data sourced from Visible Alpha consensus and actuals database, SEC Form 4 filings, company earnings transcripts and press releases, and Yahoo Finance stock price data. Peer commentary sourced from IDEXX Q2 2026, Elanco Q2 2026, Trupanion Q2 2026, and Chewy Q1 FY2026 earnings call transcripts. Prepared August 5, 2026.